A novel application of XPO1 inhibition for the treatment of myelofibrosis.

Blood Neoplasia · 2024 · PMC12082109 · PMID 40454401

Europe PMC DOI

hedged sentence

0.0545

closest p · 1.1× alpha

0.0545

boldest claim

The sentences

a strong trendP = .0545so close (0.05 < p ≤ 0.1)

The pelabresib plus ruxolitinib arm also had a strong trend toward improved TSS50 at 24 weeks ( P = .0545), which was evident across all TSS domains.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.